Health ProductsPublic Communication

Archived – Reminder: Canadian Requirements for White Blood Cell Monitoring for Patients Taking Clozaril*

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

[Text of letter begins]

Public Advisory – Health Canada Endorsed Important Safety Information on Clozaril (clozapine)

June 30, 2005

Subject: Reminder: Canadian Requirements for White Blood Cell Monitoring for Patients Taking Clozaril* (clozapine) Tablets.

Novartis Pharmaceuticals Canada Inc., in consultation with Health Canada, would like to remind you that the blood monitoring requirements related to the use of Clozaril* (clozapine) tablets have not changed in Canada.

Clozaril* (clozapine) is indicated in the management of symptoms of treatment-resistant schizophrenia. Due to the significant risk of a blood disorder associated with its use, all patients must have their blood monitored prior to starting and throughout the course of Clozaril* therapy.

While the schedule of blood monitoring requirements in the United States will be changed, the current requirements in Canada, will remain in place. Novartis Pharmaceuticals Canada Inc. does not intend to request changes to the monitoring schedule at this time.

Novartis Pharmaceuticals Canada Inc. reiterates its commitment to the delivery of quality pharmaceutical products and is committed to ensuring the timely dissemination of new information that is important to physicians and patients. If you have questions about your current prescription, please contact your physician or pharmacist.

The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of a serious or unexpected adverse reaction in patients receiving Clozaril* tablets should be reported to Novartis Pharmaceuticals Canada Inc. or Health Canada at the following addresses:

Novartis Pharmaceuticals Canada Inc.
385 Bouchard blvd,
Dorval, (QC) H9S 1A9
Phone: 1-800-363-8883

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries, please refer to contact information:

Bureau of Cardiology, Allergy and Neurological Sciences
BCANS_Enquiries@hc-sc.gc.ca
Tel: (613) 941-1499
Fax: (613) 941-1668

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For media inquiries please contact Jason Jacobs at (514) 633-7872.

* Clozaril is a registered trademark

[Text of letter ends]
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime